Attorney Docket No. 337348020US4 ereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on: Melody J. Almberg PATENT Lifar IN THE UNITED STATES PATENT AND TRADEMARK OFFICE IN RE APPLICATION OF: Andrew D.: Firlik et al. **EXAMINER:** Unknown 10/072.700 **APPLICATION NO.: ART UNIT:** 3762 RECEIVED February 7, 2002 CONF. No: 2530 FILED: FOR: METHODS AND APPARATUS FOR DEC - 9 2002 EFFECTUATING A LASTING CHANGE IN TECHNOLOGY CENTER R3700 A NEURAL-FUNCTION OF A PATIENT Information Disclosure Statement Within Three Months of Application Filing or Before First Action – 37 CFR 1.97(b) **Assistant Commissioner for Patents** Washington, D.C. 20231 Sir: 1. Timing of Submission This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 CFR 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them

 \boxtimes

2.

of record in the application.

Cited Information

 \boxtimes

Copies of the following references are enclosed:

References marked by asterisks

All cited references

The following:

found in narant LLC Application No

Copie	s of the following references can be found in parent 0.5. Application No.
	All cited references References marked by asterisks The following:
under comm citing langua prepa langua teach	following references are not in English. For each such reference, the signed has enclosed (i) a translation of the reference; (ii) a copy of a nunication from a foreign patent office or International Searching Authority the reference, (iii) a copy of a reference which appears to be an Englishage counterpart, or (iv) an English-language abstract for the reference red by a third party. Applicant has not verified that the translation, Englishage counterpart or third-party abstract is an accurate representation of the ings of the non-English reference, though, and reserves the right to instrate otherwise.
	All cited references References marked by ampersands The following:

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-0665.

5. Patent Term Adjustment (37 CFR 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Attorney Docket No. 337348020US4

Paul T. Parker

Registration No. 38,264

Respectfully submitted, Perkins Coie LLP

Correspondence Address:

Customer No. 25096 Perkins Coie LLP P.O. Box 1247 Seattle, Washington 98111-1247 (206) 583-8888

NPE	`	,	i	COMPLE IF KNOWN		
10°	<u> </u>			Application Number	10/072,700	
	INFORMATION			Confirmation Number	2530	
DEC 0 6 200Z	STATEMENT B			Filing Date	February 7, 2002	
	& Form PTO-14	49 (Modified)		First Named Inventor	Andrew D. Firlik	
TENT : TO LO CAR	Üse several she	ets if necessary)		Group Art Unit	3762	
e Irab				Examiner Name	Unknown	
Sheet	1	of	1	Attorney Docket No.	337348020US4	

							ŀ	
1 '			Code	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear		
	6,12	28,538		ischell et al.	10/03/00			
				F	RECEIVED			
	1				-			
						DEC - 9 2002		
					TECH	NOLOGY CENTER R3700	,—	
•			FO	REIGN PATENT DOCUMENTS				
Cite No.	Fore	H	ind Code		Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T	
	PCT		<u> </u>	University of Iowa Research Foundation	17/08/95			
	PCT	WO 01/97906		Advanced Bionics Corp	27/12/01			
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city								
NO.	PCT International Search Report, Applicant: Vertis Neuroscience, Inc. PCT/US02/07077, October 22, 2002, 7 pgs.							
	Cite No.	Cite No. PCT	No. NUMBER (if kr 6,128,538 Foreign Patent or Application of the No. Office NUMBER (if kr No. O	No. NUMBER (if known) 6,128,538 FOR STATE OF S	No. NUMBER (if known) of Cited Document 6,128,538	Cite No. NUMBER (if known) Name of Patentee or Inventor of Cited Document	Name of Patentee or Inventor of Cited Document Figures Appear	

EXAMINER		DATE CONSIDERED			
*EXAMINER:	itial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not				
	considered. Include copy of this form with next communication to application(s).				